Pathological Interactions Between the Endothelin-1 and the Angiotensin- Converting Enzyme Among Tunisian Coronary Patients

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2016 Nov 30

PMID 27894250

Citations 2

Authors

Abdelkader Chalghoum

Yosri Noichri

Azza Dandana

Bruno Baudin

Abdelhedi Miled

Salima Ferchichi

Affiliations

Soon will be listed here.

Abstract

Background: The correct understanding of the biochemical and metabolic interactions between coronary risk factors contribute to the exploration of cardiovascular pathophysiology and improves therapeutic care. The aim of this study was to explore the endothelin-1 (ET-1) concentration and the angiotensin converting enzyme (ACE) activity among Tunisian patients with coronary heart disease, and to investigate the metabolic relationships between these two markers,… and to assess the possible relationship between them and the different risk factors. In this present study, ET-1 concentration was determined by an analytical method (High Performance Chromatography, coupled by Mass Spectrometry), ACE activity was measured by a kinetic method for patients and healthy controls. These subjects (157 patients and 142 controls) beneficed also by a biochemical exploration (lipid, apolipoproteins and glucose profiles) to quantify cardiovascular risk.

Results: A statistically significant increase of the ET-1 concentration was found among patients compared to healthy controls (15.2 ± 5.3 nM vs 7.1 ± 2.7 nM, p < 0,00001). For the ACE activity, in spite the treatment of the majority of patients (97%) with ACE inhibitors, this activity was statistically elevated in patients compared to healthy subjects (86.7 ± 25.4 IU/L vs 42.8 ± 12.1 IU/L, p < 0.00001). Furthermore, a statistically positive correlation was identified between these two cardiac markers (r = 0.68 p < 0.00001).

Conclusion: The study of the metabolic relationship between the ET-1 and ACE among coronary patients reveals other therapeutics targets.

Citing Articles

Expression of the Endothelin-1 Gene and Its Type a Receptor including Physical Activity among Patients with Acute Myocardial Infarction.

Dabek J, Piotrkowicz J, Glogowska-Ligus J, Domagalska-Szopa M, Szopa A, Schreiber L Int J Environ Res Public Health. 2022; 19(12).

PMID: 35742539 PMC: 9224255. DOI: 10.3390/ijerph19127289.

Management of acute coronary syndrome in emergency departments: a cross sectional multicenter study (Tunisia).

Sriha Belguith A, Beltaief K, Msolli M, Bouida W, Abroug H, Ben Fredj M BMC Emerg Med. 2018; 18(1):50.

PMID: 30509187 PMC: 6276213. DOI: 10.1186/s12873-018-0201-6.

References

Russ T, Hamer M, Stamatakis E, Starr J, Batty G, Kivimaki M . Does the Framingham cardiovascular disease risk score also have predictive utility for dementia death? An individual participant meta-analysis of 11,887 men and women. Atherosclerosis. 2013; 228(1):256-8. DOI: 10.1016/j.atherosclerosis.2013.02.020. View

Cracowski J, Stanke F, Bessard G . [Endothelin-1 and cardiovascular diseases]. Rev Med Interne. 1999; 20(7):589-96. DOI: 10.1016/s0248-8663(99)80108-8. View

Rashtchizadeh N, Aghaeishahsavari M, Argani H, Noroozianavval M, Veisi P, Ghorbanihaghjo A . Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms. Clin Biochem. 2007; 40(3-4):194-200. DOI: 10.1016/j.clinbiochem.2006.10.023. View

Zhao W, Zhao D, Yan R, Sun Y . Cardiac oxidative stress and remodeling following infarction: role of NADPH oxidase. Cardiovasc Pathol. 2008; 18(3):156-66. PMC: 2693891. DOI: 10.1016/j.carpath.2007.12.013. View

Kawada T, Andou T, Fukumitsu M . Metabolic syndrome showed significant relationship with carotid atherosclerosis. Heart Vessels. 2015; 31(5):664-70. DOI: 10.1007/s00380-015-0668-y. View

Yanagisawa M, Inoue A, Ishikawa T, Kasuya Y, Kimura S, Kumagaye S . Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A. 1988; 85(18):6964-7. PMC: 282099. DOI: 10.1073/pnas.85.18.6964. View

Reddy K, Satija A . The Framingham Heart Study: impact on the prevention and control of cardiovascular diseases in India. Prog Cardiovasc Dis. 2010; 53(1):21-7. DOI: 10.1016/j.pcad.2010.02.011. View

Yanagisawa M, Masaki T . Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol. 1989; 38(12):1877-83. DOI: 10.1016/0006-2952(89)90484-x. View

Baudin B . New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med. 2002; 40(3):256-65. DOI: 10.1515/CCLM.2002.042. View

10.

Belaidi E, Godin-Ribuot D . [The endothelin system: its involvement in the cardiovascular system]. Rev Med Interne. 2010; 31(11):792-4. DOI: 10.1016/j.revmed.2009.11.011. View

11.

Chalghoum A, Noichri Y, Karkouch I, Dandana A, Baudin B, Jeridi G . Metabolic interactions between hyperhomocysteinemia and endothelin-1 among Tunisian patients with acute coronary diseases. Biol Res. 2015; 48:32. PMC: 4482036. DOI: 10.1186/s40659-015-0018-7. View

12.

Majed B, Tafflet M, Kee F, Haas B, Ferrieres J, Montaye M . External validation of the 2008 Framingham cardiovascular risk equation for CHD and stroke events in a European population of middle-aged men. The PRIME study. Prev Med. 2013; 57(1):49-54. DOI: 10.1016/j.ypmed.2013.04.003. View

13.

Frohlich J, Al-Sarraf A . Cardiovascular risk and atherosclerosis prevention. Cardiovasc Pathol. 2012; 22(1):16-8. DOI: 10.1016/j.carpath.2012.03.001. View

14.

Bello N, Mosca L . Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis. 2004; 46(4):287-95. DOI: 10.1016/j.pcad.2003.08.001. View

15.

Scheen A . Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2005; 30(6):498-505. DOI: 10.1016/s1262-3636(07)70147-7. View

16.

Demacker P, Veerkamp M, Bredie S, Marcovina S, de Graaf J, Stalenhoef A . Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis. 2001; 153(2):483-90. DOI: 10.1016/s0021-9150(00)00432-9. View

17.

Chalghoum A, Noichri Y, Chkioua L, Gammoudi I, Dandana A, Chahed H . [Study of the intronic polymorphism of the angiotensin 1 converting enzyme among coronary Tunisians]. Ann Cardiol Angeiol (Paris). 2011; 60(3):135-40. DOI: 10.1016/j.ancard.2010.12.019. View

18.

Spinarova L, Spinar J, Vasku A, Goldbergova M, Ludka O, Toman J . Big endothelin in chronic heart failure: marker of disease severity or genetic determination?. Int J Cardiol. 2004; 93(1):63-8. DOI: 10.1016/s0167-5273(03)00112-8. View

19.

Kyriakides Z, Kremastinos D, Raptis A, Johnston N, Raptis S, Webb D . Impaired effect of endothelin-1 on coronary artery stiffness in type 2 diabetes. Int J Cardiol. 2005; 112(2):207-12. DOI: 10.1016/j.ijcard.2005.09.018. View

20.

Larson A, Witman M, Guo Y, Ives S, Richardson R, Bruno R . Acute, quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower plasma angiotensin-converting enzyme activity or endothelin-1: nitric oxide. Nutr Res. 2012; 32(8):557-64. DOI: 10.1016/j.nutres.2012.06.018. View